Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.